Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Highlight
  • Published:

Haematological cancer

Adding blinatumomab to chemotherapy reduces recurrence risk in standard-risk paediatric B-ALL

Nature Reviews Clinical Oncology volume 22, page 79 (2025)Cite this article

Subjects

Access through your institution
Buy or subscribe

Despite considerable progress, B-cell acute lymphoblastic leukaemia (B-ALL) remains a major cause of cancer-related death in children. Now, data from the phase III AALL1731 trial demonstrate that adding the CD19 × CD3 bispecific T cell engager blinatumomab to chemotherapy significantly improves the outcomes of patients with standard-risk B-ALL with an average or high risk of disease relapse.

In this trial, 1,440 children (1–10 years of age) with standard-risk B-ALL with an average (n = 835) or high (n = 605) risk of relapse, based on cytogenetic features and minimal residual disease (MRD) status on completion of induction therapy, were randomly assigned (1:1) to receive two cycles of post-induction (for average-risk patients) or post-consolidation (for high-risk patients) chemotherapy with versus without blinatumomab. Disease-free survival (DFS) was the primary endpoint.

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

Original article

Download references

Author information

Authors and Affiliations

  1. Nature Reviews Clinical Oncology http://www.nature.com/nrclinonc

    Peter Sidaway

Authors
  1. Peter Sidaway
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Peter Sidaway.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sidaway, P. Adding blinatumomab to chemotherapy reduces recurrence risk in standard-risk paediatric B-ALL. Nat Rev Clin Oncol 22, 79 (2025). https://doi.org/10.1038/s41571-024-00980-1

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41571-024-00980-1

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer